Aprea Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and a continued net loss. The company generated grant revenue of $1,848 for the three months ended September 30, 2025, a decrease of approximately 99% compared to $354,621 in the same period last year. For the nine months ended September 30, 2025, total grant revenue was $282,422, down from $1,296,764 in the prior year. The decrease in revenue is attributed to reduced grant funding from the National Cancer Institute.
Operating expenses for the third quarter were $3.1 million, a reduction of 30% from $4.5 million in the same quarter of 2024. This decline was primarily driven by lower research and development costs, which fell to $1.6 million from $2.8 million year-over-year. The decrease in R&D expenses is linked to the voluntary pause in patient enrollment for the ATRN-119 clinical trial and reduced costs associated with the APR-1051 trial. General and administrative expenses also decreased slightly to $1.5 million from $1.6 million, reflecting cost-cutting measures.
Aprea's net loss for the third quarter was $2.97 million, an improvement from a net loss of $3.78 million in the same period last year. For the nine months ended September 30, 2025, the company reported a net loss of $10.14 million, compared to $10.06 million in the prior year. The accumulated deficit as of September 30, 2025, stood at $331.2 million, indicating the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs.
In terms of operational developments, Aprea is focusing on its two main product candidates: APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor. The company has paused new patient enrollment for ATRN-119 while exploring combination therapies with other agents, including radiation therapy. Aprea's cash and cash equivalents totaled $13.7 million as of September 30, 2025, which the company believes will not be sufficient to fund its operations for the next twelve months. As a result, Aprea is actively seeking additional funding to support its ongoing clinical trials and operational needs.
Looking ahead, Aprea anticipates that its expenses will continue to rise as it progresses through clinical trials and seeks to expand its product pipeline. The company has indicated that it may need to significantly reduce expenditures if additional funding is not secured. Aprea's management remains focused on advancing its clinical programs and exploring strategic partnerships to enhance its financial position and operational capabilities.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology through synthetic lethality. It develops small molecule inhibitors targeting DNA damage response (DDR) pathways, including WEE1 and ATR kinases, to selectively kill cancer cells with specific genetic mutations while minimizing toxicity. Aprea’s pipeline focuses on advanced solid tumors, leveraging integrated discovery platforms to identify novel targets and biomarkers, retaining global rights for development and commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.